THR-184

Synthetic Peptide / TGF Β Pathway ModulatorRx: InvestigationalCompound: Investigational

Also known as: BMP-7 peptide mimetic, THR-184, Thrasos-184

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Summary

THR-184 is an investigational BMP-7 mimetic peptide developed for the prevention of cardiac surgery-associated acute kidney injury (CSA-AKI). It was evaluated in clinical trials (AKIN-1/TRIBE-AKI) in high-risk cardiac surgery patients. The peptide aims to protect renal tubular cells from ischemia-reperfusion injury during major surgery by activating cytoprotective BMP signaling pathways.

Mechanism of Action

THR-184 is a synthetic peptide analogue of bone morphogenetic protein-7 (BMP-7) that acts as a BMP receptor agonist, activating the SMAD1/5/8 signaling pathway. It promotes renal tubular cell survival, reduces apoptosis, inhibits TGF-β1-mediated fibrosis, and attenuates the epithelial-to-mesenchymal transition (EMT) in renal tubular epithelial cells, thereby providing cytoprotective and anti-fibrotic effects in the kidney.

Routes of Administration

Intravenous

Goals & Uses

  • Reduction of renal tubular apoptosisCell SurvivalLow
  • Prevention of acute kidney injuryRenoprotectionModerate
  • Attenuation of ischemia-reperfusion injuryCytoprotectionModerate
  • Reduction of renal fibrosisAntifibroticLow

Contraindications

  • Hypersensitivity to THR-184 or excipientsAllergic/ImmunologicHigh
  • Active malignancy with BMP pathway involvementOncologyModerate

Adverse Effects

  • Electrolyte disturbancesMetabolicUnknown
  • HypotensionCardiovascularUnknownLow blood pressure
  • NauseaGastrointestinalUnknownFeeling of sickness or urge to vomit
  • Injection site / infusion reactionsLocal/SystemicUnknown

Drug Interactions

  • TGF-β inhibitorsLow
  • DiureticsLowMay worsen dehydration or electrolyte imbalance

Population Constraints

  • Patients with end-stage renal diseaseRenal ImpairmentRelative
  • Pediatric patientsAgeRelative
  • Pregnant or lactating womenReproductiveRelative
  • Patients with known BMP pathway malignanciesOncologyRelative

Regulatory Status

  • European UnionInvestigationalClinical trials conducted in European centers; no EMA approval
  • United StatesInvestigationalEvaluated under FDA IND; no approved indication as of knowledge cutoff
  • United KingdomInvestigationalNo MHRA approval; participated in multi-center trials

Not approved by FDA, EMA, or other regulatory agencies. Investigated under IND/clinical trial frameworks. Development was primarily led by Thrasos Therapeutics (Canada). Phase 2 trials were conducted; no Phase 3 program has been publicly announced.

Evidence & Sources

No sources recorded yet.

Browse All PeptidesBuild My Stack